{"id":13175,"date":"2024-01-18T14:05:44","date_gmt":"2024-01-18T13:05:44","guid":{"rendered":"https:\/\/www.corp.gruenhorn.de\/?p=13175"},"modified":"2024-07-26T08:21:28","modified_gmt":"2024-07-26T08:21:28","slug":"canymed-und-somai-pharmaceuticals-starten-10-millionen-eur-strategische-vertriebspartnerschaft-fuer-cannabis-extrakte","status":"publish","type":"post","link":"https:\/\/www.gruenhorn.group\/en\/canymed-und-somai-pharmaceuticals-starten-10-millionen-eur-strategische-vertriebspartnerschaft-fuer-cannabis-extrakte\/","title":{"rendered":"Canymed and SOMA\u00cd Pharmaceuticals Launch \u20ac10 Million Strategic Distribution Partnership for Cannabis Extracts"},"content":{"rendered":"

The Gr\u00fcnhorn network expands, paving the way for SOMA\u00cd Pharmaceuticals from Portugal to enter the German medical cannabis market. <\/b><\/p>\n

Canymed GmbH, a pharmaceutical wholesaler for medical cannabis within the Gr\u00fcnhorn network, has entered into a \u20ac10 million distribution and marketing agreement with SOMA\u00cd Pharmaceuticals. This marks another milestone for the economic growth of the Leipzig-based Gr\u00fcnhorn network. <\/b><\/p>\n

The collaboration began in Q1 2024, combining the expertise of Canymed, a leading German medical cannabis company, with SOMA\u00cd's international experience in developing personalized cannabis-based medications. This partnership enables SOMA\u00cd to leverage Canymed's extensive AMG \u00a775 distribution network and go-to-market capabilities. The aim is to supply high-quality pharmaceutical cannabinoid-based products to Germany to meet the growing demand. Regulatory, pharmaceutical, and political challenges under the planned reclassification of cannabis as non-narcotic require significant local expertise in the dynamic market. Canymed will act as the market coordinator between SOMA\u00cd, the Gr\u00fcnhorn network, pharmacies, and medical professionals in Germany to deliver products of excellent pharmaceutical quality to patients.<\/p>\n

\"Canymed is proud of the partnership with SOMA\u00cd Pharmaceuticals and its contribution to the distribution of advanced pharmaceutical solutions for the use of medical cannabis,<\/i>\" says Matthias Fischer, founder and CEO of Canymed. \"Together, we look forward to making a positive impact on healthcare in Germany.\"<\/i><\/p>\n

Co-Branding with Gr\u00fcnhorn<\/h3>\n
With this partnership, Canymed takes another strategic step towards establishing a co-branded product line based on cannabis in Germany. Through the cannabis-specialized Gr\u00fcnhorn Pharmacy, the laboratory team of pharmacists, chemists, and biochemists determines the exact active ingredient concentration of cannabis flowers and extracts using GC-MS and HPLC analyses. The new product line offers patients in Germany a personalized selection of medical formulations from cannabinoids, terpenes, and flavonoids with varying THC and CBD contents (including 25:1, 10:10, and 50:1). This is unique in Germany and Europe and ensures that the desired effect meets the medical therapy requirements. Based on the analysis, the capsules and extracts from SOMA\u00cd can be integrated into the portfolio of the Gr\u00fcnhorn network and the German market.<\/div>\n
\"The Gr\u00fcnhorn network is pleased with the combination of SOMA\u00cd's expertise as a renowned manufacturer of cannabis products and the trust we enjoy as a health brand in the cannabis sector. This partnership aligns with our mission to provide patients with widespread access to innovative and effective health options,<\/i>\" says Stefan Fritsch, founder of the Gr\u00fcnhorn network.<\/div>\n
Michael Sassano, founder and CEO of SOMA\u00cd Pharmaceuticals, says, \"We are excited about the opportunities this partnership offers SOMA\u00cd Pharmaceuticals to provide innovative cannabinoid-based medicines to patients worldwide. The cooperation with Canymed GmbH and the Gr\u00fcnhorn network underscores our commitment to meeting the evolving healthcare needs in Germany.\" <\/i><\/div>","protected":false},"excerpt":{"rendered":"

Das Gr\u00fcnhorn-Netzwerk w\u00e4chst und ebnet SOMA\u00cd Pharmaceuticals aus Portugal den Weg in den deutschen Markt f\u00fcr medizinisches Cannabis. Die Canymed GmbH, ein pharmazeutischer Gro\u00dfh\u00e4ndler f\u00fcr medizinisches Cannabis im Gr\u00fcnhorn-Netzwerk, hat mit SOMA\u00cd Pharmaceuticals eine Vertriebs- und Vermarktungsvereinbarung \u00fcber zehn Millionen Euro geschlossen. Damit wurde ein weiterer Meilenstein f\u00fcr das Wachstum des wirtschaftsstarken Leipziger Gr\u00fcnhorn-Netzwerks gelegt. […]<\/p>\n","protected":false},"author":1,"featured_media":13708,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_uag_custom_page_level_css":"","footnotes":""},"categories":[1],"tags":[],"class_list":["post-13175","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pressemeldungen"],"uagb_featured_image_src":{"full":["https:\/\/www.gruenhorn.group\/wp-content\/uploads\/2024\/01\/Canymed-und-SOMAI-Pharmaceuticals-starten-10-Millionen-EUR-strategische-Vertriebspartnerschaft-fuer-Cannabis-Extrakte.webp",1200,600,false],"thumbnail":["https:\/\/www.gruenhorn.group\/wp-content\/uploads\/2024\/01\/Canymed-und-SOMAI-Pharmaceuticals-starten-10-Millionen-EUR-strategische-Vertriebspartnerschaft-fuer-Cannabis-Extrakte-150x150.webp",150,150,true],"medium":["https:\/\/www.gruenhorn.group\/wp-content\/uploads\/2024\/01\/Canymed-und-SOMAI-Pharmaceuticals-starten-10-Millionen-EUR-strategische-Vertriebspartnerschaft-fuer-Cannabis-Extrakte-300x150.webp",300,150,true],"medium_large":["https:\/\/www.gruenhorn.group\/wp-content\/uploads\/2024\/01\/Canymed-und-SOMAI-Pharmaceuticals-starten-10-Millionen-EUR-strategische-Vertriebspartnerschaft-fuer-Cannabis-Extrakte-768x384.webp",768,384,true],"large":["https:\/\/www.gruenhorn.group\/wp-content\/uploads\/2024\/01\/Canymed-und-SOMAI-Pharmaceuticals-starten-10-Millionen-EUR-strategische-Vertriebspartnerschaft-fuer-Cannabis-Extrakte-1024x512.webp",1024,512,true],"1536x1536":["https:\/\/www.gruenhorn.group\/wp-content\/uploads\/2024\/01\/Canymed-und-SOMAI-Pharmaceuticals-starten-10-Millionen-EUR-strategische-Vertriebspartnerschaft-fuer-Cannabis-Extrakte.webp",1200,600,false],"2048x2048":["https:\/\/www.gruenhorn.group\/wp-content\/uploads\/2024\/01\/Canymed-und-SOMAI-Pharmaceuticals-starten-10-Millionen-EUR-strategische-Vertriebspartnerschaft-fuer-Cannabis-Extrakte.webp",1200,600,false],"trp-custom-language-flag":["https:\/\/www.gruenhorn.group\/wp-content\/uploads\/2024\/01\/Canymed-und-SOMAI-Pharmaceuticals-starten-10-Millionen-EUR-strategische-Vertriebspartnerschaft-fuer-Cannabis-Extrakte.webp",18,9,false]},"uagb_author_info":{"display_name":"rsuessenbach","author_link":"https:\/\/www.gruenhorn.group\/en\/author\/rsuessenbach\/"},"uagb_comment_info":0,"uagb_excerpt":"Das Gr\u00fcnhorn-Netzwerk w\u00e4chst und ebnet SOMA\u00cd Pharmaceuticals aus Portugal den Weg in den deutschen Markt f\u00fcr medizinisches Cannabis. Die Canymed GmbH, ein pharmazeutischer Gro\u00dfh\u00e4ndler f\u00fcr medizinisches Cannabis im Gr\u00fcnhorn-Netzwerk, hat mit SOMA\u00cd Pharmaceuticals eine Vertriebs- und Vermarktungsvereinbarung \u00fcber zehn Millionen Euro geschlossen. Damit wurde ein weiterer Meilenstein f\u00fcr das Wachstum des wirtschaftsstarken Leipziger Gr\u00fcnhorn-Netzwerks gelegt.…","_links":{"self":[{"href":"https:\/\/www.gruenhorn.group\/en\/wp-json\/wp\/v2\/posts\/13175"}],"collection":[{"href":"https:\/\/www.gruenhorn.group\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.gruenhorn.group\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.gruenhorn.group\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.gruenhorn.group\/en\/wp-json\/wp\/v2\/comments?post=13175"}],"version-history":[{"count":1,"href":"https:\/\/www.gruenhorn.group\/en\/wp-json\/wp\/v2\/posts\/13175\/revisions"}],"predecessor-version":[{"id":13350,"href":"https:\/\/www.gruenhorn.group\/en\/wp-json\/wp\/v2\/posts\/13175\/revisions\/13350"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.gruenhorn.group\/en\/wp-json\/wp\/v2\/media\/13708"}],"wp:attachment":[{"href":"https:\/\/www.gruenhorn.group\/en\/wp-json\/wp\/v2\/media?parent=13175"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.gruenhorn.group\/en\/wp-json\/wp\/v2\/categories?post=13175"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.gruenhorn.group\/en\/wp-json\/wp\/v2\/tags?post=13175"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}